Business
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting
Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery PETACH TIKVA, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will present at the 4
About this update from Polypid Ltd.
[{"type":"image","alt":"PolyPid Ltd.; DPLEX","displaySize":"","headline":null,"caption":"PolyPid Ltd.; DPLEX","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":81,"url":"https://media.zenfs.com/en/globenewswire.com/192c8e54c53ba3b93553e120225504cb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ua2hyutrnzPk2bIgA4NSdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMw--/https://media.zenfs.com/en/globenewswire.com/192c8e54c53ba3b93553e120225504cb","width":300,"height":81}},"lazy":false},{"type":"text","content":"Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery","length":196,"tagName":"p"},{"type":"text","content":"PETACH TIKVA, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will present at the 45th Annual Meeting of the Surgical Infection Society, taking place on May 5-6, 2026, at the Coronado Island Marriott in Coronado, California. The presentation will focus on a detailed analysis of the ASEPSIS (Additional treatment, Serous discharge, Erythema, Purulent exudate, Separation of deep tissues, Isolation of bacteria, and prolonged Stay as inpatient) score data from the Company's Phase 3 SHIELD II trial of D-PLEX100.","length":735,"tagName":"p"},{"type":"text","content":"The presentation will be delivered by Dr. Robert G. Sawyer, MD, FSIS, FACS, FCCM, FIDSA, a Professor and Chair of the Department of Surgery at Western Michigan University Homer Stryker M.D. School of Medicine. Dr. Sawyer also serves as Senior Associate Dean for Research and Editor-in-Chief of the journal Surgical Infections.","length":326,"tagName":"p"},{"type":"text","content":"The ASEPSIS score is a validated, objective clinical scoring system used to assess the severity of surgical wound infections. It integrates parameters such as wound appearance, antibiotic use, drainage of pus, isolation of pathogenic bacteria, and length of hospital stay. As previously reported in the SHIELD II topline results, treatment with D-PLEX100 together with the standard of care resulted in a 64% relative risk red...